Supreme Court refuses to hear Saffran v Johnson & Johnson appeal

Managing IP is part of Legal Benchmarking Limited, 1-2 Paris Gardens, London, SE1 8ND

Copyright © Legal Benchmarking Limited and its affiliated companies 2026

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Supreme Court refuses to hear Saffran v Johnson & Johnson appeal

The US Supreme Court refused on Monday to hear an appeal from a doctor asking it to reinstate a $482 million patent infringement award against Johnson & Johnson subsidiary Cordis

The court declined to hear Saffran v Johnson & Johnson, in which radiologist Bruce Saffran claimed Cordis infringed a patent he obtained in 1997 in making its Cypher brand of drug-eluting stents, tiny mesh tubes used to prop open weak or narrow arteries.

A district court jury previously found that Cordis violate the patent. But a split Federal Circuit panel did not defer to the district court’s claim construction. The Federal Circuit changed the claim construction and overturned the district court’s finding that Cordis infringed the patent.

Saffran asked the appeals court to put his case on hold and reconsider it alongside Lighting Ballast v Philips, which concerns similar issues about the deference the Federal Circuit should give to a district court’s claim construction. But the Federal Circuit refused.

The Supreme Court’s refusal to accept the case means that Federal Circuit’s decision will stand.

The Supreme Court did not decide whether to accept the WildTangentvUltramercial case on Monday, instead electing to put the question of whether to hear it on hold. If the court chooses to accept that case, it will consider when a patent’s reference to a computer or the Internet is sufficient to make an otherwise unpatentable abstract idea eligible for patent protection.

The court may be waiting to decide whether to accept certiorari of WildTangentvUltramercial until it has resolved Alice v CLS Bank, which concerns similar issues and which the Supreme Court agreed to hear in December. Arguments in that case will take place on March 31 and a decision is expected by the end of June 2014.

more from across site and SHARED ros bottom lb

More from across our site

Top talking points also included news of an appellate ruling concerning ‘Pisco’ and Indian drugmakers gearing up to launch generic versions of Ozempic as Novo Nordisk’s patent expires
The government’s keenly awaited view on AI and copyright has positive themes but leaves rights owners wanting, says Rebecca Newman at Addleshaw Goddard
While IP Australia’s updated manual could be favourable to computer-implemented inventions, stakeholders would like to see whether a consistent and reliable standard is followed during actual examination
UKIPO will remain a competitive option as long as efficient service continues
A future opt-out has not been ruled out, but practitioners warn that the UK could fall behind in the AI race
US patent lawyers say they are increasingly advising clients on China strategies as corporations seek to gain leverage in enforcement, licensing, and supply chain management
Mike Rueckheim reunites with 12 of his former Winston & Strawn colleagues as King & Spalding continues aggressive hiring streak
As global commerce continues to expand through e-commerce platforms and digital marketplaces, protecting brands has become a growing challenge for organisations worldwide. Counterfeiting, intellectual property infringement, and online brand abuse are increasing across industries, making brand protection strategies a critical priority for businesses.
Henrik Holzapfel and Chuck Larsen of McDermott Will & Schulte explain why a Court of Appeal ruling could promote access to justice and present a growth opportunity for litigation finance
A co-partner in charge says the UK prosecution teams are a ‘vital’ part of the firm’s offering, while praising a key injunction win
Gift this article